
USA - NASDAQ:IIN - US46121H1095 - Common Stock
The current stock price of IIN is 24.24 null. In the past month the price increased by 0.92%. In the past year, price increased by 8.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B |
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. The company is headquartered in Arden Hills, Minnesota and currently employs 873 full-time employees. The firm serves as a JDM partner to medical device original equipment manufacturers (OEMs) by designing, developing, engineering, manufacturing, packaging and distributing micro medical devices components and subassemblies for medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. The company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete catheter-based and body-worn devices for medical device manufacturers. The firm serves its market by offering medical device manufacturers, which have the capabilities to design, develop, manufacture, package and distribute medical devices. The company operates globally with facilities in Minnesota, Illinois, California, Singapore, Indonesia and Germany.
INTRICON CORP
1260 Red Fox Road
Arden Hills MINNESOTA 55112 US
CEO: Scott Longval
Employees: 873
Phone: 16516369770.0
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. The company is headquartered in Arden Hills, Minnesota and currently employs 873 full-time employees. The firm serves as a JDM partner to medical device original equipment manufacturers (OEMs) by designing, developing, engineering, manufacturing, packaging and distributing micro medical devices components and subassemblies for medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. The company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete catheter-based and body-worn devices for medical device manufacturers. The firm serves its market by offering medical device manufacturers, which have the capabilities to design, develop, manufacture, package and distribute medical devices. The company operates globally with facilities in Minnesota, Illinois, California, Singapore, Indonesia and Germany.
The current stock price of IIN is 24.24 null. The price increased by 0.04% in the last trading session.
IIN does not pay a dividend.
IIN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
5 analysts have analysed IIN and the average price target is 25.5 null. This implies a price increase of 5.2% is expected in the next year compared to the current price of 24.24.
The PE ratio for INTRICON CORP (IIN) is 44.07. This is based on the reported non-GAAP earnings per share of 0.55 and the current share price of 24.24 null.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IIN.
ChartMill assigns a technical rating of 7 / 10 to IIN. When comparing the yearly performance of all stocks, IIN is one of the better performing stocks in the market, outperforming 94.95% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to IIN. The financial health of IIN is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months IIN reported a non-GAAP Earnings per Share(EPS) of 0.55. The EPS increased by 1200% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1.17% | ||
| ROA | -1.17% | ||
| ROE | 1.03% | ||
| Debt/Equity | 0 |
5 analysts have analysed IIN and the average price target is 25.5 null. This implies a price increase of 5.2% is expected in the next year compared to the current price of 24.24.
For the next year, analysts expect an EPS growth of -13.69% and a revenue growth 10.43% for IIN